Cargando…

Decitabine-Mediated Upregulation of CSPG4 in Ovarian Carcinoma Cells Enables Targeting by CSPG4-Specific CAR-T Cells

SIMPLE SUMMARY: Cancer therapy by specifically redirected T cells has revolutionized the field of oncology. However, the repertoire of targetable antigens is small. Here, we use the FDA-approved drug decitabine to upregulate the surface antigen CSPG4 on CSPG4-negative ovarian carcinoma cells. By opt...

Descripción completa

Detalles Bibliográficos
Autores principales:	Harrer, Dennis Christoph, Schenkel, Charlotte, Berking, Carola, Herr, Wolfgang, Abken, Hinrich, Dörrie, Jan, Schaft, Niels
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2022
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9599610/ https://www.ncbi.nlm.nih.gov/pubmed/36291817 http://dx.doi.org/10.3390/cancers14205033

Ejemplares similares

CSPG4 as Target for CAR-T-Cell Therapy of Various Tumor Entities–Merits and Challenges
por: Harrer, Dennis C., et al.
Publicado: (2019)

CSPG4-Specific CAR T Cells for High-Risk Childhood B Cell Precursor Leukemia
por: Harrer, Dennis C., et al.
Publicado: (2019)

Clinical-Scale Production of CAR-T Cells for the Treatment of Melanoma Patients by mRNA Transfection of a CSPG4-Specific CAR under Full GMP Compliance
por: Wiesinger, Manuel, et al.
Publicado: (2019)

Combining CSPG4-CAR and CD20-CCR for treatment of metastatic melanoma
por: Teppert, Karin, et al.
Publicado: (2023)

Arming T Cells with a gp100-Specific TCR and a CSPG4-Specific CAR Using Combined DNA- and RNA-Based Receptor Transfer
por: Simon, Bianca, et al.
Publicado: (2019)

CARs and Drugs: Pharmacological Ways of Boosting CAR-T-Cell Therapy
por: Harrer, Dennis Christoph, et al.
Publicado: (2023)

The regulatory mechanisms of NG2/CSPG4 expression
por: Ampofo, Emmanuel, et al.
Publicado: (2017)

IRF4 downregulation improves sensitivity and endurance of CAR T cell functional capacities
por: Harrer, Dennis Christoph, et al.
Publicado: (2023)

The Significance of Chondroitin Sulfate Proteoglycan 4 (CSPG4) in Human Gliomas
por: Schiffer, Davide, et al.
Publicado: (2018)

Theranostic Impact of NG2/CSPG4 Proteoglycan in Cancer
por: Nicolosi, Pier Andrea, et al.
Publicado: (2015)

CSPG4: a prototype oncoantigen for translational immunotherapy studies
por: Rolih, Valeria, et al.
Publicado: (2017)

Cspg4(high) microglia contribute to microgliosis during neurodegeneration
por: Liu, Ya-jing, et al.
Publicado: (2023)

Immunotherapeutic Targeting of NG2/CSPG4 in Solid Organ Cancers
por: Zhang, Hongyu, et al.
Publicado: (2022)

Identification of CSPG4 as a promising target for translational combinatorial approaches in osteosarcoma
por: Riccardo, Federica, et al.
Publicado: (2019)

NG2/CSPG4 regulates cartilage degeneration during TMJ osteoarthritis
por: Reed, David A., et al.
Publicado: (2022)

Expression of chondroitin sulfate proteoglycan 4 (CSPG4) in melanoma cells is downregulated upon inhibition of BRAF
por: Uranowska, Karolina, et al.
Publicado: (2021)

CAR Triggered Release of Type-1 Interferon Limits CAR T-Cell Activities by an Artificial Negative Autocrine Loop
por: Harrer, Dennis Christoph, et al.
Publicado: (2022)

CSPG4: A Target for Selective Delivery of Human Cytolytic Fusion Proteins and TRAIL
por: Jordaan, Sandra, et al.
Publicado: (2017)

CSPG4 Expression in GIST Is Associated with Better Prognosis and Strong Cytotoxic Immune Response
por: de Nonneville, Alexandre, et al.
Publicado: (2022)

Targeting the melanoma-associated antigen CSPG4 with HLA-C*07:01-restricted T-cell receptors
por: Kropp, Korbinian N., et al.
Publicado: (2023)

Localization and Developmental Expression Patterns of CSPG in the RCS Rat Retina
por: Chen, Li-Feng, et al.
Publicado: (2011)

Chondroitin Sulphate Proteoglycan 4 (NG2/CSPG4) Localization in Low- and High-Grade Gliomas
por: Mellai, Marta, et al.
Publicado: (2020)

CSPG4 CAR-redirected Cytokine Induced Killer lymphocytes (CIK) as effective cellular immunotherapy for HLA class I defective melanoma
por: Giraudo, Lidia, et al.
Publicado: (2023)

Chondroitin Sulfate Proteoglycan CSPG4 as a Novel Hypoxia-Sensitive Marker in Pancreatic Tumors
por: Keleg, Shereen, et al.
Publicado: (2014)

Impact of KMT2A Rearrangement and CSPG4 Expression in Pediatric Acute Myeloid Leukemia
por: Hoffmeister, Lina Marie, et al.
Publicado: (2021)

NG2/CSPG4 attenuates motility in mandibular fibrochondrocytes under serum starvation conditions
por: Ahn, Shin Young, et al.
Publicado: (2023)

Targeting glioblastoma with NK cells and mAb against NG2/CSPG4 prolongs animal survival
por: Poli, Aurélie, et al.
Publicado: (2013)

Internalization and trafficking of CSPG-bound recombinant VAR2CSA lectins in cancer cells
por: Wang, Chris Kedong, et al.
Publicado: (2022)

In vivo safety profile of a CSPG4-directed IgE antibody in an immunocompetent rat model
por: Williams, Iwan P., et al.
Publicado: (2019)

Identification of a germline CSPG4 variation in a family with neurofibromatosis type 1-like phenotype
por: Bai, Zhuanli, et al.
Publicado: (2021)

CSPG4 expression in soft tissue sarcomas is associated with poor prognosis and low cytotoxic immune response
por: Boudin, Laurys, et al.
Publicado: (2022)

Nectin-3 and shed forms of CSPG4 can serve as epithelial cell receptors for Clostridioides difficile TcdB
por: Childress, Kevin O., et al.
Publicado: (2023)

The extent of extra-axonal tissue damage determines the levels of CSPG upregulation and the success of experimental axon regeneration in the CNS
por: Kim, Juhwan, et al.
Publicado: (2018)

Candidate CSPG4 mutations and induced pluripotent stem cell modeling implicate oligodendrocyte progenitor cell dysfunction in familial schizophrenia
por: de Vrij, Femke M., et al.
Publicado: (2018)

Expression of the progenitor marker NG2/CSPG4 predicts poor survival and resistance to ionising radiation in glioblastoma
por: Svendsen, Agnete, et al.
Publicado: (2011)

Targeting the NG2/CSPG4 Proteoglycan Retards Tumour Growth and Angiogenesis in Preclinical Models of GBM and Melanoma
por: Wang, Jian, et al.
Publicado: (2011)

Diversified Expression of NG2/CSPG4 Isoforms in Glioblastoma and Human Foetal Brain Identifies Pericyte Subsets
por: Girolamo, Francesco, et al.
Publicado: (2013)

Structural basis for CSPG4 as a receptor for TcdB and a therapeutic target in Clostridioides difficile infection
por: Chen, Peng, et al.
Publicado: (2021)

Discovery of Hippo signaling as a regulator of CSPG4 expression and as a therapeutic target for Clostridioides difficile disease
por: Larabee, Jason L., et al.
Publicado: (2023)

Chondroitin Sulfate Proteoglycan-4 (CSPG4)-Specific Monoclonal Antibody 225.28 in Detection of Acute Myeloid Leukemia Blasts
por: Fenton, Moon, et al.
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_m6ncdl5b50mmqs2f9saa78gghp